Z79.633 — Long term (current) use of mitotic inhibitor
Is Z79.633 billable?
Yes — Z79.633 is billable for FY2027. Z79.633 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. Z79.633 may be submitted for encounters from October 1, 2026 through September 30, 2027.
Z79.633 at a glance
| Code | Z79.633 |
|---|---|
| Description | Long term (current) use of mitotic inhibitor |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
What Medicare edits apply to Z79.633?
The Medicare Code Editor screens inpatient claims before they are grouped. These edits name Z79.633 directly.
CMS will reject this code as the principal diagnosis on an inpatient claim. It describes something other than the condition chiefly responsible for the admission.
Which MS-DRGs does Z79.633 group to?
Z79.633 sits in MDC 23 and helps define the logic of 2 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 949Aftercare with CC/MCCmedical
- 950Aftercare without CC/MCCmedical
How is Z79.633 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to Z79.633. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Long-term › mitotic inhibitor (current) (prophylactic) drug therapy (use of)
- Long-term › paclitaxel (current) (prophylactic) drug therapy (use of)
- Long-term › plant alkaloids (current) (prophylactic) drug therapy (use of)
- Long-term › vinblastine (current) (prophylactic) drug therapy (use of)
- Long-term › vincristine (current) (prophylactic) drug therapy (use of)
Inclusion terms
Alternative wording in documentation that is classified to Z79.633.
- Long term (current) use of paclitaxel
- Long term (current) use of plant alkaloids
- Long term (current) use of vinblastine
- Long term (current) use of vincristine
Excludes2 — not included here — inherited from Z79
The conditions below are not part of Z79.633, but a patient may have both at the same time. When documentation supports it, Z79.633 and the excluded code may both be reported.
Excludes2 — not included here — inherited from Z79.6
The conditions below are not part of Z79.633, but a patient may have both at the same time. When documentation supports it, Z79.633 and the excluded code may both be reported.
Code also — inherited from Z77-Z99
Two codes may be needed to describe the condition fully. Whether Z79.633 is sequenced first depends on the reason for the encounter.
- any follow-up examination (Z08-Z09)
Code also — inherited from Z79
Two codes may be needed to describe the condition fully. Whether Z79.633 is sequenced first depends on the reason for the encounter.
- any therapeutic drug level monitoring (Z51.81)
How long has Z79.633 existed?
Z79.633 first appears in FY2023.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.